Not all that glitters is gold

被引：0
作者：
Gazitt, Y [1 ]
机构：
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA
来源：
BLOOD | 2005年 / 106卷 / 13期
关键词：
D O I：
10.1182/blood-2005-09-3835
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple myeloma (MM) is a difficult disease to treat because of confounding factors such as genetic heterogeneity and the multiplicity and redundancy of survival pathways constitutively activated in this disease.
引用
收藏
页码：4025 / 4026
页数：2
相关论文
共 7 条
  • [1] Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
    Bharti, AC
    Shishodia, S
    Reuben, JM
    Weber, D
    Alexanian, R
    Raj-Vadhan, S
    Estrov, Z
    Talpaz, M
    Aggarwal, BB
    [J]. BLOOD, 2004, 103 (08) : 3175 - 3184
  • [2] Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
    Eskens, FALM
    Awada, A
    Cutler, DL
    de Jonge, MJA
    Luyten, GPM
    Faber, MN
    Statkevich, P
    Sparreboom, A
    Verweij, J
    Hanauske, AR
    Piccart, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 1167 - 1175
  • [3] Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
    Hideshima, T
    Chauhan, D
    Hayashi, T
    Akiyama, M
    Mitsiades, N
    Mitsiades, C
    Podar, K
    Munshi, NC
    Richardson, PG
    Anderson, KC
    [J]. ONCOGENE, 2003, 22 (52) : 8386 - 8393
  • [4] 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells
    Kulp, SK
    Yang, YT
    Hung, CC
    Chen, KF
    Lai, JP
    Tseng, PH
    Fowble, JW
    Ward, PJ
    Chen, CS
    [J]. CANCER RESEARCH, 2004, 64 (04) : 1444 - 1451
  • [5] Clinical update: proteasome inhibitors in hematologic malignancies
    Richardson, P
    [J]. CANCER TREATMENT REVIEWS, 2003, 29 : 33 - 39
  • [6] Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma:: Correlation with suppression of COX-2 synthesis
    Shishodia, S
    Koul, D
    Aggarwal, BB
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (03) : 2011 - 2022
  • [7] Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis
    Takada, Y
    Khuri, FR
    Aggarwal, BB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (25) : 26287 - 26299
1